Drugs / AVI-7288
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01566877 Comparator | May 2013 → Jan 2014 | Marburg hemorrhagic fever | Sarepta Therapeutics, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-07-22 | Sarepta Therapeutics, Inc. | Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platform sarepta.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVI-7288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01566877 ↗ |
| Modality | Antisense oligonucleotide | “AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™)” NCT01566877 ↗ |
| Route | Intravenous | “given by IV infusion over 30 minutes once a day for 14 days” NCT01566877 ↗ |